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Background:Group IIA secreted phospholipase A2 (hGIIA) is a bifunctional protein that regulates arachidonic acidmetab-
olism by both catalysis-dependent and catalysis-independent mechanisms.
Results: Selective inhibition of the catalysis-independent signaling function perturbs a hGIIA-vimentin interaction in rheuma-
toid synoviocytes.
Conclusion: The signaling and catalytic functions of hGIIA are pharmacologically separable.
Significance: Functionally selective inhibitors of hGIIA may provide new avenues for investigation and treatment of immune-
mediated inflammation.
Human group IIA secreted phospholipase A2 (hGIIA) pro-
motes tumor growth and inflammation and can act indepen-
dently of its well described catalytic lipase activity via an alter-
native poorly understood signaling pathway. With six
chemically diverse inhibitors we show that it is possible to selec-
tively inhibit hGIIA signaling over catalysis, and x-ray crystal
structures illustrate that signaling involves a pharmacologically
distinct surface to the catalytic site.Wedemonstrate in rheuma-
toid fibroblast-like synoviocytes that non-catalytic signaling is
associatedwith rapid internalization of the enzyme and colocal-
ization with vimentin. Trafficking of exogenous hGIIA was
monitored with immunofluorescence studies, which revealed
that vimentin localization is disrupted by inhibitors of signaling
that belong to a rare class of smallmolecule inhibitors thatmod-
ulate protein-protein interactions. This study provides struc-
tural and pharmacological evidence for an association between
vimentin, hGIIA, and arachidonic acid metabolism in synovial
inflammation, avenues for selective interrogation of hGIIA sig-
naling, and new strategies for therapeutic hGIIA inhibitor
design.
Phospholipase A2 (PLA2)6 enzymes (EC 3.1.1.4) catalyze the
hydrolysis of the Sn2 ester bond of glycerophospholipids,
thereby regulating the release of biologically active fatty acids
and lysophospholipids from membrane phospholipid pools.
These lipids are further metabolized within cells to 100
potent autocrine and paracrine lipid mediators. The ei-
cosanoids, which are products of arachidonic acid metabolism
by cyclooxygenase, lipoxygenase, and P450 epoxygenase
enzymes or by non-enzymatic oxidation, are well recognized
modulators of both cell and organ function (1–3). Cell type-
specific regulation of the production, concentration, and rela-
tive abundance of individual lipid mediators in response to
external stimuli serves as an integrated, self-referent, and self-
limiting biochemical signaling network in higher organisms.
This lipid-signaling network regulates embryonic stem cell dif-
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ferentiation anddevelopment and in adult organismsmaintains
physiological homeostasis in disparate organs such as the gas-
trointestinal, cardiovascular, renal, reproductive, nervous, and
immune systems.
In recent decades manifold PLA2 proteins with widely diver-
gent selectivity for phospholipid substrate and diverse mecha-
nisms by which their production and enzyme activity are regu-
lated have been discovered in mammals. There are 22 human
PLA2 enzymes that are divided into 15 subgroups defined by
structural similarity, catalytic mechanism, calcium require-
ment, and whether they are secreted (4). This structural and
functional diversity within a single enzyme class suggests that
the activation and expression of PLA2 enzymes may be an
important control point at which the responsiveness of lipid
mediator biosynthesis pathways to external stimuli is regulated
and highlights the need for a more detailed understanding of
the function and expression of each enzyme.
Aberrant control of eicosanoid signaling contributes to a
wide range of human pathological states from headaches to
certain cancers. In this context, PLA2 enzymes have been tar-
geted in the hope that limiting substrate supply rather than
selectively blocking the production of particularmediatorsmay
be of therapeutic benefit (4). The secreted enzymes (sPLA2s) (5)
have been most aggressively targeted thus far. A pan Group
IIA/Group V/Group X sPLA2 inhibitor has been tested in clin-
ical trials in sepsis (6), rheumatoid arthritis (7), and coronary
artery disease (8) with limited success, likely due to the lack of
subtype selectivity of this compound and further highlighting a
need for a better understanding of the selectivity of these inhib-
itors and the function of sPLA2 subtypes in eicosanoid metab-
olism in vivo.
Themolecular basis for Group IIA sPLA2 (hGIIA) catalysis is
well characterized (5) and can be potently inhibited with sub-
strate analogues or by covalent modification of active site resi-
dues. However, recent studies show that hGIIA is a bifunctional
protein contributing to arachidonic acid metabolism in cells
derived from pathological states by acting both as an enzyme
capable of releasing arachidonic acid from microvesicles shed
by activated cells and as a catalytic activity-independent
indirect amplifier of intracellular eicosanoid production
through up-regulation of the cytosolic PLA2-cyclooxygenase-2
(COX-2) pathway (9). The bifunctional nature of hGIIA in reg-
ulating arachidonic acid metabolism raises important ques-
tions about the relative contribution of each function to the
production of inflammatorymediators and the subsequent pro-
motion of inflammation. Further the findings raise the possibil-
ity of selective pharmacological inhibition of each function as a
means of investigating the importance of these roles.
Neither themechanism of hGIIA-mediated signaling nor the
relative importance of the signaling function in the promotion
of inflammation is known. Here we characterize a chemically
diverse set of hGIIA inhibitors in each of two functionally selec-
tive assays. We show that there is no correlation between the
potency of inhibitors in blocking hGIIA catalysis and their
potency in blocking prostaglandin E2 (PGE2) production in
human rheumatoid fibroblast-like synoviocytes (FLSs), which
is a catalytic activity-independent function of hGIIA. Further-
more, we identified three classes of hGIIA inhibitors, those that
are (i) selective for catalysis, (ii) non-selective, or (iii) selective
for catalysis-independent activity, and determined the crystal
structures of hGIIA bound to class (i) and (ii) inhibitors. In
combination with the functional assays, these structures indi-
cate that inhibitors of hGIIA signaling in rheumatoid FLS cells
operate by perturbing a vimentin binding surface on hGIIA.
Finally we demonstrate that the catalysis-independent function
of exogenous hGIIA is associatedwith rapid internalization and
colocalization with vimentin in FLSs that is dramatically dis-
rupted by both dual-function and signaling-selective inhibitors
but not by catalysis-selective inhibition. Thus, these inhibitors
of hGIIA signaling belong to a rare class of small molecule
inhibitors that act by modulating protein-protein interactions.
The structures also suggest that the signaling and catalytic
actions of hGIIA may be mutually exclusive, with transition
between the twomodes of action regulated by a conformational
switch that is unique to the hGIIA subtype involving displace-
ment of His-6. These results provide a solid foundation for the
design of further functionally selective inhibitors that will be
useful in assessing how the pathophysiology of sPLA2 segre-
gates into its catalytic or non-catalytic actions in vivo and in
turn the feasibility of developing efficacious sPLA2 inhibitors.
EXPERIMENTAL PROCEDURES
Materials—hGIIA protein was expressed using the stably
transfected hGIIA-expressing CHOK1 cell line 5A2 (10) grown
on alginate beads and cultivated in a stirred fermenter with a
10-liter working volume. hGIIA was purified and quantified as
described previously (10). LY311727 was a gift from Lilly,
KH064was purchased fromSigma, andMe-Indoxam, an indole
derivative of the indolizine inhibitor indoxam (11), was synthe-
sized as described (12). The cyclic peptide inhibitors cyclo-FL-
SYR and cyclo-2-Nal-LS-2-Nal-R were synthesized by Auspep
(Melbourne, Australia).
Enzyme Activity Assay—hGIIA catalytic activity was mea-
sured with a colorimetric microtiter plate, mixed-micelle assay
(13) using diheptanoylthiophosphatidylcholine as substrate
(Cayman Chemical, Ann Arbor, MI) as described (9) with the
following modifications. Absorbance was read at 405 nm over
70–90 min on a SPECTRAmax 250 microtiter plate spectro-
photometer. Statistical data analysis was performed in
Microsoft Excel, and curve fitting and kinetic data analysis
were performed using Sigma Plot (SYSTAT, San Jose, CA).
Purified hGIIA had a specific activity of 27.8  2.3 mol of
diheptanoylthiophosphatidylcholine/min/mg of protein.
hGIIA Signaling Assay—FLS cells were isolated and cultured
from synovial tissue of patients diagnosed with rheumatoid
arthritis (14) undergoing joint surgery at St. Vincent’s Hospital,
Sydney, using procedures approved by the St. Vincent’s Hospi-
tal Ethics Committee as described (9, 10). Cells (passage 3–10)
were plated on 96-well microtiter plates (Greiner), grown to
85–95% confluence, and stimulated for 18 h in serum-free
media (DMEM/Ham’s F-12 with 0.1% BSA, 200 l) with 10
ng/ml TNF (20 l). hGIIA (20 l, 4 g/ml) with or without
inhibitor was added simultaneously with TNF in inhibitor
assays and with various inhibitor concentrations (0.3–10
g/ml) in dose-response experiments as indicated. Inhibitors
(dissolved in DMSO and diluted in serum-free media) were
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added (20 l) where appropriate. Culture medium PGE2 was
quantified by enzyme immunoassay (Cayman Chemical). Cells
were detached with 0.05% (w/v) trypsin, 0.53 mM EDTA, and
triplicate wells were combined and centrifuged at 8000 g for
10 min at 4 °C. Cold lysis solution (1% (v/v) Nonidet P-40, 0.5%
(w/v) sodiumdeoxycholate, 0.1% (w/v) SDS, and 1mMEGTA in
PBSwith freshly added protease inhibitors 50g/ml aprotonin,
200 M leupeptin, and 1 mM phenylmethylsulfonyl fluoride)
was added to the cells and incubated overnight at 4 °C. PGE2
was normalized for cell count and quantified bymeasuring total
protein in lysates with a detergent-compatible protein assay
(Bio-Rad). Independent experiments were performed using
cells derived from separate patients.
Crystallization—Pure concentrated hGIIA (5–20 mg/ml)
was buffer-exchanged into crystallization buffer containing 0.1
MTris-HCl, pH7.4, 10mMCaCl2, 0.5mM-octyl glucoside, and
2 MNaCl precipitate, with 5-kDaUltrafree-MCCentrifugal Fil-
ter Units (Millipore, Billerica, MA). Where appropriate, puri-
fied hGIIA (1 mg/ml) was chemically modified with p-bro-
mophenacyl bromide (BPB) (Sigma) by coincubation at room
temperature overnight with 1 mM BPB in 0.1 M Tris-HCl, pH
8.0, 0.1 M NaCl, and 0.7 mM EDTA. The hGIIA-BPB complex
was then exchanged into crystallization buffer containing 0.1 M
Tris-HCl, pH 7.4, 10mMCaCl2, 0.5mM-octyl glucoside, and 1
MNaCl, concentrated 10-fold ,then flash-frozen in liquid nitro-
gen and stored at 80 °C for use in activity assays or crystalli-
zation trials.
Crystals were grown by the hanging-drop vapor-diffusion
method using 24-well tissue-culture plates (Linbro, ICN Bio-
medicals). Drops were equilibrated with crystallization buffer
with higherNaCl concentrations between 3 and 5 M. Coverslips
were purchased pre-siliconized from Hampton Research
(Laguna Niguel, CA). 2-l drops were used in the presence of
the inhibitor at approximately 2–5-fold molar excess over pro-
tein. Solutions and tissue-culture plates were all stored at crys-
tal growth temperature (293 K) in a SanyoMIR-2530 incubator
(Sanyo Electric) unless otherwise stated. Macroseeding was
performed in some instances by immersing nylon loops or
human hair into drops containing crushed native crystals then
streaking the hair across fresh drops containing enzyme with
inhibitor.
Structure Determination—Crystals were mounted onto a
nylon loop and flash frozen in liquid nitrogen without cryopro-
tectant and stored in liquid nitrogen for data collection. X-ray
diffraction data were collected (  0.5°) at a wavelength of
0.9002 Å with the crystals under a nitrogen stream at 100 K at
beamline 14-BMC at the Advanced Photon Source in Chicago
on a Area Detector Systems Corporation Quantam-315
charged coupled device detector. Diffraction was indexed and
integrated with Denzo and scaled with Scalepack using the
HKL-2000 program package (15). Datasets were solved using
molecular replacement with either Molrep or Phaser in the
CCP4 program suite (16). Coot (17) was used to build and fit
models into electron density, and refinement was carried out
using Refmac 5.0 in the CCP4 program suite. Models were
refined to convergence before waters were added, and inhibi-
tors were not used in rounds of refinement until all identifiable
waters were built. The stereochemistry of the structures was
assessed using the Molprobity internet server (18). Structures
were overlaid using least squares refinement using Lsqkab in
the CCP4 program suite. Ray traced images were generated
using the PyMOL (19). All 1Fo 1Fc electron density difference
maps of inhibitors were generated before building any atoms
into the inhibitor density to minimize phase bias. The protein
structure data from this publication have been submitted to the
Protein Data Bank database and assigned the following acces-
sion codes: 3U8B, native hGIIA; 3U8I, hGIIA-BPB complex;
3U8H, hGIIA-KH064 complex; 3U8D, hGIIA-LY311727
complex.
Immunofluorescence and Imaging—When indicated, FLSs
(RA61 and RA57; passage 8–13) were treated with hGIIA (2.5
g/ml) diluted in PBS, 0.1% BSA for 2 min on ice. Cells were
then fixed for 2.5 min in 4% paraformaldehyde, 0.1% Triton
X-100 for 10min, blocked for 30min in blocking solution (0.1%
BSA and 10% donkey serum in PBS), and incubated with 4A1
(20) (6 g/ml), an anti-hGIIA murine monoclonal primary
antibody, in blocking solution for 1 h. Cells were washed in PBS
and incubated for 30 min in the dark with Alexa Fluor 488
donkey anti-mouse secondary antibody (Invitrogen). After
washing, cells were incubated againwith 4g/ml anti-vimentin
antibody (Santa Cruz Biotechnology C-20) in blocking solution
for 1 h, washed, and incubated in the dark with Alexa Fluor 555
donkey anti-goat secondary antibody for 30 min. Cells were
then mounted in ProLong Gold antifade medium (Invitrogen).
Immunofluorescence was collected using laser scanning confo-
cal microscope (Leica TCS SP upright). Images shown are sin-
gle sections taken from z-stacks acquired using the manufac-
turer’s software. ImageJ (NIH) was used to invert colors,
generate merge pictures, and add scale bars. The figure were
assembled, and levels were adjusted uniformly using Photo-
Shop CS4 (Adobe).
RESULTS
Functionally Selective Inhibition of hGIIA—We have previ-
ously shown that exogenous addition of hGIIA causes up-reg-
ulation of COX-2 expression in FLSs that, on costimulation
with the cytokine TNF, causes an increase in PGE2 production
(10). Here we show that covalent modification of the active site
His-48 residue with the irreversible inhibitor BPB (21) has no
effect on dose-dependent stimulation of PGE2 production in
rheumatoid FLS cells yet completely abrogates enzyme-
dependent hydrolysis of diheptanoylthiophosphatidylcholine
micelles (Fig. 1, A and B). Thus, these data together with our
similar observations with the activity impaired hGIIA mutant
H48Q (9) establish unequivocally that hGIIA stimulation of
PGE2 production and up-regulation of COX-2 occurs in-
dependently of its enzyme activity in FLSs. Indeed, two cyclic
peptide hGIIA inhibitors (22) appear to selectively inhibit PGE2
production while being only very weak inhibitors of dihep-
tanoylthiophosphatidylcholine hydrolysis, with maximal inhi-
bition only observed with more than 1 106-fold molar excess
of peptide (Fig. 1, C and D). These peptides, cyclo-FLSYR (cF)
and the analog cyclo-(2-Nal)-LS-(2-Nal)-R (c2) were derived
from residues 70–74 of the primary sequence of hGIIA (22, 23).
The ability to selectively inhibit the catalytic and non-catalytic
actions of hGIIA establishes that these two functions may be
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pharmacologically separated and that inhibition of the signal-
ing function of hGIIA does not depend on direct perturbation
of the well characterized His-48—Asp-99 hGIIA catalytic site
(5). Finally, the competitive inhibitors Me-Indoxam (12),
LY311727 (24), and KH064 (25) dose-dependently inhibited
both diheptanoylthiophosphatidylcholine hydrolysis, as well as
PGE2 production in FLSs (Fig. 1, C and D). However, their rel-
ative potency in inhibition of catalytic activity (Me-Indoxam
LY311727 KH064, spanning an 8-fold range in IC50) appears
to be unrelated to their relative potency against cell signaling
(KH064 LY311727Me-Indoxam, spanning a 2-fold range
in IC50). The hGIIA used in these experiments was expressed in
mammalian cells; however, lipopolysaccharide (LPS) contami-
nation would nicely explain why BPB-inactivated hGIIA and
the H48Qmutant (9) elicit PGE2 production. Importantly, this
LPS hypothesis is ruled out by the fact that both cyclic peptides
as well as KH064, LY311727, and Me-Indoxam block hGIIA-
dependent PGE2 production.
As hGIIA signaling is likely mediated by protein-protein
interactions rather than by catalysis, inhibitors of signaling
probably belong to a relatively rare class of small-molecule
inhibitors that operate by disrupting surface protein interac-
tions. To understand how inhibition of hGIIA signaling is
mediated and to identify the relevant binding surface and in
turn the relevant interacting protein, we determined the crystal
structure of the native enzyme in the presence of the active site
calcium and in complex with BPB, KH064, and LY311727.
The Crystal Structure of the hGIIA with the Active Site
Calcium—Although the structure of the hGIIA without inhib-
itor bound has been known for well over two decades (26),
remarkably there is no native structuremodeled with the active
site calcium ion bound, which is required for the catalytic activ-
FIGURE 1. Selective inhibition of hGIIA catalytic activity and signaling. The effect of BPB modification of hGIIA (BPB in A or hGIIA-BPB in B) relative to
unmodified hGIIA (native inAor native hGIIA in B) on catalytic activity (A) anddose-dependent hGIIA-mediated PGE2 production (B) is shown.C andD show the
dose-dependent effect of non-covalent hGIIA inhibitors on native hGIIA catalytic activity and hGIIA-mediated PGE2 production, respectively. Catalytic activity
was determined using a commercially availablemixed-micelle colorimetric assay as described in “Experimental Procedures”. The assaywas run for 70–90min,
and the initial stable gradientwasused to calculate reaction rates. Data (A andC) arepresented as%of uninhibitednativehGIIA activity (specific activity, 27.8
2.3mol of diheptanoylthiophosphatidylcholine/min/mg or protein) and are themeans S.E. of 2–3 independent experiments each performed in triplicate
with data combined for analysis. PGE2 productionwas assessed in cultured FLS cells. Triplicate wells with 90% confluent FLS cells (n 5) in DMEM/Ham’s F-12
containing 0.1% BSAwere stimulated with TNF (10 ng/ml) together with indicated concentrations of either BPB-modified hGIIA or native hGIIA (B). In panel D,
native hGIIA with inhibitors at the indicated concentrations was added to cells along with TNF. In all cases cells were incubated for 16–20 h. PGE2 concentra-
tionsweredetermined in triplicate fromharvestedmedia using aPGE2 enzyme-linked immunoassay as describedunder “Experimental Procedures.” Cellswere
then harvested, and PGE2 productionwas normalized for protein concentration of the total cell lysate of three combinedwells, as determined by a detergent-
compatible protein assay. Data are themean S.E. of 2–5 independent experiments performed in triplicate on primary cells from 2–3 different patients with
data combined for analysis.
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ity of hGIIA. Furthermore, asmutations in the invariant Gly-30
and the conserved Leu-31 of the calcium binding loop affect
sPLA2 binding to its M-type receptor (27), the presence of the
calcium may affect the non-catalytic function of hGIIA. To
address this, we crystallized hGIIA in similar conditions to
those used by Scott et al. (28) with 10 mM CaCl2. Hexagonal
crystals grew overnight (space group P6122), and diffraction
data were collected to 2.26 Å resolution. Diffraction data,
refinement, and model validation statistics are summarized in
Table 1 and 2. There was a strong density peak in the active site
calcium-binding site. The center of the peak was 2.3 Å from
the carbonyl oxygen atoms of His-28, Gly-30, and Gly-32
and the carboxylate moiety of Asp-49 (Fig. 2, A and B). This
typifies the expected stereochemistry of a calcium-binding site.
A calcium ion was modeled into the peak and its occupancy
refined to 63%, which resulted in minimal residual 1Fo  1Fc
difference density. Attempts to refine a fully occupied water
molecule in the density peak resulted in significant positive
1Fo 1Fc difference density.
The Structure of the hGIIA-BPBComplex—hGIIAwas chem-
ically modified with BPB and crystallized. The crystallographic
structure of BPB-inhibited hGIIA was determined from x-ray
diffraction data to 1.1 Å resolution from these crystals and has
two molecules in the asymmetric unit of a P41 unit cell. This is
the highest resolution crystal structure of any PLA2 enzyme,
and individual atoms are clearly resolvable within the polypep-
tide chain. Diffraction data, refinement, and model validation
statistics are summarized in Tables 1 and 2. BPB is covalently
bound to the N of the active site His-48 residue and
found wholly within the active site cavity (Fig. 2, C and D,
supplemental Fig. 1). BPB binds in the same way to bovine pan-
creatic (29) and snake toxin sPLA2 enzymes (30, 31). The phe-
nyl ring on BPB is in contact with Phe-5, Phe-93, and Gly-30 in
the hydrophobic active site cavity, and the bromide atom
appears to cause a subtle movement in the His-6 side chain
away from the active site cavity with the N1 deviating by1.3
Å from the native structure (supplemental Fig. 1). Interestingly
the hGIIA-BPB structure retains the active site calcium. This is
unique to the BPB-inhibited sPLA2 structures known to date.
The calcium ion is coordinated by the carbonyl oxygen atoms of
His-28, Gly-30, and Gly-32 on the putative calcium binding
loop (28) and a carboxyl oxygen on the Asp-49 side chain. In
addition, for the first time, two structural water molecules that
coordinate the active site calcium are clearly resolvable. One of
these water molecules is on the surface of the enzyme exposed
to bulk solvent, and the other (HOH) is in the active site cavity
and sterically clashes (2.4 Å) with the carbonyl carbon of BPB
(supplemental Fig. 1). Thus, a consequence of the presence of
the active site calcium ion in a BPB-modified hGIIA structure is
that the active site cavity must be co-occupied by a water mol-
ecule and BPB, which forces an apparently energetically unfa-
vorable interaction. This explains both the weaker affinity of
calcium for the covalently modified enzyme complex and how
mM concentrations of calcium can inhibit BPB modification
(21, 32, 33). In addition, the active site calcium shifts away from
the inhibitor in the active site cavity by 0.5 Å, and subsequently
the coordinating calcium binding loop moves substantially to
compensate with C deviations up to 2.6 Å. Furthermore, the
Asp-49 bidentate coordination to the calcium found in the
native structure is disrupted with only one of the O oxygens
TABLE 1
Data collection and refinement statistics
Values in parentheses are for highest resolution shell.
hGIIA Native BPB KH064 LY311727
Data collection
Space group P6122 P41 P31 P3121
Cell dimensions
a, b, c (Å) 74.7, 74.7, 89.2 70.4, 70.4, 47.3 74.8, 74.8, 49.9 74.4, 74.4, 93.7
, ,  (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0
Resolution (Å) 36.7-2.30 (2.42-2.30) 40.0-1.10 (1.16-1.10) 29.9-2.30 (2.42-2.30) 19.8-1.80 (1.90-1.80)
Rmerge 6.6 (67.0) 13.5 (56.6) 5.5 (24.2) 7.9 (48.2)
Mean I/I 23.0 (4.0) 7.5 (2.1) 11.8 (3.4) 18.3 (3.7)
Completeness (%) 99.3 (99.3) 99.9 (99.9) 97.8 (98.5) 99.9 (98.4)
Redundancy 10.4 (11.1) 4.3 (3.4) 2.8 (2.8) 4.7 (4.5)
Refinement
Resolution (Å) 24.4-2.3 34.3-1.10 24.8-2.30 19.8-1.80
No. reflections 6,909 91,537 12,907 28,010
Rwork/Rfree 20.7/25.7 16.5/18.6 19.2/22.5 12.1/18.9
No. atoms (no H) 1023 2430 2093 2358
Average B-factor 66.7 16.6 21.9 20.2
Root mean square deviations
Bond lengths (Å) 0.018 0.010 0.008 0.016
Bond angles (°) 1.77 1.33 1.10 1.21
TABLE 2
Molprobity structure validation statistics
Native hGIIA hGIIA-BPB hGIIA-KH064 hGIIA-LY311727
Clashscorea, all atom 4.32 5.42 3.7 6.2
Rotamer outliers 0.00% 0.00% 0.48 0.48
Ramachandran outliers 0.00% 0.00% 0.00% 0.41
Ramachandran favored 97.5% 97.0% 97.13 96.7%
C deviations0.25Å 0 0 0 0
Overall molprobity scoreb 100th n 8821 (2.3 0.25 Å) 70th n 159 (0.09-1 Å) 100th n 8909 (2.3 0.25 Å) 92nd n 11,256 (1.8 0.25Å)
a Clash score is the number of steric overlaps (0.4 Å) per 1000 residues.
b Values written as percentile where 100th percentile is the best among n structures of comparable resolution (in parentheses).
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coordinating to the calcium and the other hydrogen bonded to
HOH.
TheCrystal Structure of the hGIIA-LY311727Complex—The
crystals of the hGIIA-LY311727 complex diffracted to 1.8 Å
resolution and are primitive hexagonal, belonging to space
group P3121. The crystals were twinned with a pseudo-P6122
symmetry. Diffraction data, refinement, and model validation
statistics are summarized in Tables 1 and 2. As seen in the
structure of hGIIA complexed to indole 8, which differs from
LY311727 by a single methyl group (24), a phosphate, and car-
bonyl oxygen of LY311727, coordinates to the active site cal-
cium and a primary amine makes polar contacts with His-48
and Asp-49 residues (Fig. 2, E and F). In addition, the hydro-
phobic indole and phenyl ring makes several hydrophobic
interactions along the active site cavity. The additional methyl
group on LY311727, absent in indole 8, is buried deep within
the hydrophobic cavity and improves the surface complimen-
tarity between the inhibitor and hGIIA. It makes additional
hydrophobic contacts with Phe-5, Phe-98, and Ile-9 explain-
ing the 2-fold higher potency of LY311727 in comparison to
indole 8 (24) (Fig. 2F). Despite their similarities, the hGIIA-
LY311727 structure crystallized in a different space group,
with two monomers in the asymmetric unit (Fig. 2E), sug-
gesting that LY311727 but not indole 8 binding disturbs a
crystal contact.
The Crystal Structure of the hGIIA-KH064 Complex—A
structure of the hGIIA-KH064 complex was previously
reported by Hansford et al. (25). However, the inhibitor was
modeled in alternate conformations, with steric clashes with
the calcium binding loop (PDB accession code 1KQU; supple-
mental Fig. 2,A and B). To resolve any ambiguity in the binding
mode of KH064, we independently determined the crystal
structure of the same complex. As described (25), the hGIIA-
KH064 complex crystallized with 2monomers in the asymmet-
ric unit with inhibitors bound to bothmonomers (Fig. 2G). The
structure of the enzyme in each monomer was well preserved
with an overall C RMS deviation of 0.16 Å. The inhibitor was
clearly seen in the active site cavity of both monomers, coordi-
nated to the active site calcium in unbiased 1Fo 1Fc difference
electron density, and all regions of both inhibitors were well
defined and able to be modeled without ambiguity (Fig. 2H).
The inhibitor comprises a charged head group and two hydro-
phobic tails mimicking the Sn1 and Sn2 fatty acid in a glycero-
phospholipid substrate. The head group and the Sn2 tail of both
inhibitors in the asymmetric unit bound to the active site cal-
cium and the hydrophobic cavity, respectively, in a similar fash-
ion. In contrast to the published hGIIA-KH064 structure (PDB
code 1KQU), the conformation of the Sn1 tail is not in alternate
conformations but in distinct complementary conformations
in each monomer that do not clash with the calcium binding
loop (Fig. 2H and supplemental Fig. 2, C and D). The phenyl
ring extends beyond the active site where it interacts with the
equivalent moiety in the second monomer in the asymmetric
unit, possibly creating a hydrophobic dimeric interface.
Inhibitors of hGIIA Signaling Perturb Surface Properties with-
out Disrupting the Overall Structure—We compared the struc-
ture of native hGIIA containing the active site calciumwith the
structures of the inactivated H48Q mutant (PDB accession
code 1N28 (34)), hGIIA-BPB, hGIIA-LY311727, and hGIIA-
KH064. The overall fold of the protein was conserved across
all structures, indicating that inhibitors of the signaling
function of hGIIA do not induce gross conformational
FIGURE 2. Crystal structures of native and inhibited hGIIA structures. The asymmetric units of native (A), BPB-modified (C), LY311727-bound (E), and
KH064-bound (G) hGIIA are rendered in blue ribbon format with active site calcium ions shown as green spheres and inhibitors shown in yellow in stick format.
Where applicable, C rootmean square deviation values from thenative structure are shownunderneath their corresponding chains.Bdepicts the coordination
of the active site calcium in the native hGIIA structure. Unbiased 1Fo 1Fc density of BPB (D), LY311727 (F), and KH064 (H) calculated before the inclusion of
inhibitors in rounds of refinement are displayed in green mesh contoured at 3 . Final 2Fo 1Fc density is also contoured at 1.5  around selected residues in
(D).
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changes (Fig. 3). However, inhibitors of hGIIA signaling
(KH064 and LY311727), but not the catalytic-selective
inhibitor BPB, perturb the surface properties at the entrance
to the active site in two ways. First, they displace the His-6
side chain, resulting in the formation of a new hydrogen
bond between the His-6 N1 and the O of Glu-17 (Fig. 4A).
Second, the His-6 side chain is replaced by a large hydropho-
bic surface created by phenyl rings of LY311727 and KH064
(Fig. 4, B and C). This exposed hydrophobic surface spans
40 Å2 over the surface of the enzyme for the hGIIA-
LY311727 complex and more than 80 Å2 for the hGIIA-
KH064 complex.
The Surface That Is Perturbed by Inhibitors of hGIIA Signal-
ing Correlates to the Vimentin Binding Surface—hGIIA has a
large number of solvent-exposed lysine and arginine side chains
on the enzyme surface that impart an electropositive coat that is
important for heparan sulfate proteoglycan binding (35).
Charge reversal of clusters of proximal lysine and arginine
residues on the face of hGIIA that includes the entrance to
the active site cavity dramatically reduced binding to vimen-
tin, whereas mutations on the opposite side do not (36). In
addition, the V3W mutation on the N-terminal helix
increased binding to vimentin 3-fold over wild type. Thus,
the location of the vimentin binding face correlates with the
displaced His-6 side chain and perturbed surface in signal-
ing-inhibited hGIIA structures (Fig. 4, B–D). These data
identify vimentin as a potential binding partner for hGIIA in
mediating its signaling function. To test this possibility, we
examined the localization of hGIIA when it was added exog-
enously to FLS cells.
hGIIAColocalizes with Vimentin—hGIIAwas applied to FLS
cells grown on coverslips for a short time, and its localization
was determined by confocal immunofluorescence microscopy
of fixed and permeabilized cells using the hGIIA-specific
monoclonal antibody 4A1 (20). The antibody showednegligible
staining of cells in the absence of added hGIIA (Fig. 5A). On
exogenous addition, hGIIA was rapidly internalized by FLS
cells and localized in the cytoplasm in filamentous strands with
perinuclear staining, with negligible hGIIA detected in the
nucleus (Fig. 5B). Internalization occurredwhen cells were pre-
incubated at 4 °C with no obvious effect on the time course,
indicating that internalization is likely an energy-independent
event. Cells were also stained with anti-vimentin antibodies
that showed the well known cytoplasmic and perinuclear stain-
ing pattern seen in mesenchymal cells (Fig. 5C). In dual immu-
nofluorescence studies, hGIIA colocalized with vimentin (Fig.
5D, supplemental Figs. 3 and 4).
Signaling Inhibitors Perturb the hGIIA-Vimentin Interaction—
To determine the effect of inhibitors on the hGIIA-vimentin
interaction, we repeated the co-immunofluorescence micros-
FIGURE3. InhibitionofhGIIAactivitydoesnotalter itsoverall structure.Backbone tracesof nativehGIIA (white), theH48Qmutant (green), andwhenbound
to BPB (yellow), LY311727 (blue), and KH064 (red), are overlaid inA. Calcium ions are rendered as spheres. B shows a trace of the C rootmean square deviations
of mutant or inhibited structures from the native enzyme.
FIGURE 4. Structural changes induced by inhibitors of hGIIA signaling. A, His-6 is displayed in white for signaling active hGIIA structures (native, H48Q
mutant, andhGIIA-BPB) and inblue for signaling inhibited structures (hGIIA-LY311727andhGIIA-KH064) Thehydrogenbond formedbetweenHis-6 andGlu-17
of the hGIIA-LY311727 structures is also labeled. Inhibitors are shown in yellow. Arginine and lysinemutations that inhibit or alter hGIIA binding to vimentin are
colored in green in B—D, and those that do not inhibit vimentin binding are colored in red. The displacedHis-6 side chain and the location of the V3Wmutation
that increases affinity to vimentin are colored inmagenta and blue, respectively, on the hGIIA-KH064 (B) and the hGIIA-LY311727 (C) complexes. The opposite
face of hGIIA-LY311727 is displayed in panel D.
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copy experiments in the presence of catalysis selective (BPB),
signaling-selective (c2 and cF), and non-selective (KH064 and
LY311727) inhibitors. Apart from BPB, which becomes cova-
lently bound to the enzyme, inhibitors were incubated with
hGIIA before addition to FLSs and dual immunofluorescence
labeling. The inhibitors had no observable effect on rapid inter-
nalization of hGIIA (Fig. 6, supplemental Fig. 5), and BPB non-
modified and modified enzyme colocalized to vimentin (Fig. 6,
A and B, supplemental Fig. 5, A and B). In contrast, in the pres-
ence of KH064, c2, and cF, hGIIA staining was diffuse in the
cytoplasm (Fig. 6, D–F, supplemental Fig. 5, D–F) rather than
colocalized with vimentin as seen in the absence of inhibitor
(Fig. 6C, supplemental Fig. 5C). In the presence of LY311727,
hGIIA staining was also more diffuse than control; however,
some colocalization with vimentin was still observable at the
concentration used (arrowheads in Fig. 6G and supplemental
Fig. 5G), possibly reflecting differences in the potency of the
two compounds in the signaling assay (KH064  LY311727)
relative to the enzyme inhibition assay (Fig. 1).
FIGURE 5. hGIIA internalizes rapidly and co-localizes with vimentin.
Immunofluorescence microscopy on cells stained with anti-hGIIA antibody
(4A1 (20)) and/or anti-vimentin antibody. A, cells were stained for hGIIA pri-
mary antibody alone and subsequently with both 488 and 555 secondary
antibodies in the absence of hGIIA treatment and imaged in both 488 nm
(hGIIA) and 555 nm (vimentin) channels. Exogenous hGIIA was applied, and
cells were stained for hGIIA alone (B), vimentin alone (C), or hGIIA and vimen-
tin in D and imaged as in A as described under “Experimental Procedures.”
Cells were RA61 human rheumatoid FLSs. Columns 1–3 show vimentin
(green), hGIIA (red), and a merge image, respectively. Scale bars represent 20
m.
FIGURE6.Functionallyselective inhibitionofvimentincolocalization. Immu-
nofluorescence microscopy on RA61 FLSs treated with exogenous hGIIA alone
(A) or hGIIA incubated with BPB (B). In a separate experiment RA61 FLSs were
treated with exogenous hGIIA alone (C), hGIIA incubated with KH064 (D), hGIIA
incubated with c2 (E), hGIIA incubated with cF (F), or hGIIA incubated with
LY311727 (G). Staining and imaging of both hGIIA and vimentin was performed
in all experiments as in Fig. 5 and described under “Experimental Procedures.”
Columns1–3 showvimentin (green), hGIIA (red), andamerge image, respectively.
Scale bars represent 20m.
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DISCUSSION
Recent studies have shown that hGIIA catalysis and signaling
independently regulate arachidonic acid metabolism in cells
depending on the biochemical context of the protein. For
example, as shown here, hGIIA-dependent PGE2 production
and induction of COX-2 (9) in rheumatoid synovial cells is
dependent solely on the signaling function of hGIIA. In con-
trast, the up-regulation of prostate cancer cell proliferation by
exogenous hGIIA requires the catalytic function of hGIIA (37),
as abrogation of catalytic activity with the H48Qmutation also
abrogates the proliferative capacity of hGIIA. Our observation
that these functions may be pharmacologically separated raises
the possibility of development of potent and selective inhibitors
of either catalysis or signaling that are active in vivo that might
refine the specificity of the dual-function indole inhibitors
tested thus far in the clinic. Current activity-selective inhibitors
such as BPB are not subtype-specific in that they covalently
modify histidines of several target proteins, and the structural
studies presented here may aid in the design of more specific
catalysis-selective inhibitors. In addition, of the 10 human
sPLA2 enzymes, 6 are known to bind to protein partners (38).
The sPLA2 enzymes have a highly conserved tertiary structure
and catalytic site; however, they vary significantly in primary
sequence (38), suggesting that development of functionally
selective inhibitors may be possible and of benefit in dissecting
out the mechanism of action of these enzymes in different bio-
logical contexts. Such inhibitors may also be useful in targeting
rheumatoid arthritis, as in vivo animal model studies indicate
that selective inhibition of hGIIA over other sPLA2 enzymes is
likely to be advantageous (39).
His-6 is unique to hGIIA in the family of sPLA2 enzymes. In
all structures of signaling active proteins (native, hGIIA-BPB,
and the H48Q mutant), His-6 blocks substrate access to the
active site cavity, suggesting that it must be displaced for sub-
strate binding and catalysis to occur. This is indeed the case in
the crystal structure of hGIIA bound to a transition state analog
(28). Furthermore, in the hGIIA-transition state analog struc-
ture the His-6 is stabilized by a hydrogen bond between His-6
N1 and the O of Glu 17, which appears to be a hallmark of
signaling inhibited hGIIA in rheumatoid FLS cells (Fig. 4A).
Taken together, these data suggest that catalysis and signaling
may be mutually exclusive and that His-6 may uniquely act as a
switch in hGIIA between its signaling and catalytic modes of
action.
These structures coupled with the pharmacological data on
the inhibitors presented here raised the possibility that signal-
ing inhibitors perturb the binding surface between vimentin
and hGIIA, consistent with the observation that LY311727 is
able to inhibit vimentin binding in vitro (36). Our immunoflu-
orescence studies establish that exogenous hGIIA does indeed
rapidly internalize in FLSs and very rapidly co-localizes with
intracellular vimentin filaments. Importantly, abrogation of
catalytic activity alone is insufficient to perturb hGIIA-vimen-
tin colocalization. Furthermore, as predicted by the structural
analysis, inhibitors that block hGIIA-mediated signaling, either
selectively (c2 and cF) or non-selectively (LY311727 and
KH064), also block hGIIA colocalization to vimentin.
These studies provide pharmacological and structural evi-
dence for the interaction between vimentin and hGIIA having a
role in the catalysis-independent function of hGIIA in rheuma-
toid FLSs that warrants further investigation. In the presence of
a cytokine, the intracellular enzyme cPLA2- (cytosolic
PLA2-, Group IVA PLA2) is stimulated, resulting in arachi-
donic acid flux to COX-2. This together with the hGIIA-medi-
ated increase in COX-2 protein leads to a significant up-regu-
lation of prostaglandin production (9). Importantly, the studies
imply that perturbation of this interaction is a plausible mech-
anism by which hGIIA-mediated eicosanoid production is
blocked in these cells by both selective and non-selective sig-
naling inhibitors. The structural data presented support such a
mechanism, as inhibition of catalysis alone, without perturbing
the known vimentin binding surface of hGIIA, is insufficient to
block hGIIA-mediated eicosanoid production or to perturb
the vimentin-hGIIA interaction. These findings identify the
hGIIA-vimentin association as an important target for further
study with respect to hGIIA function in regulating eicosanoid
biosynthesis and raise important questions about the mecha-
nism by which hGIIA colocalization could mediate up-regula-
tion of COX-2.
The ability of these inhibitors to interfere with hGIIA signal-
ing and to disrupt an interaction with vimentin provides the
first evidence for a possible link between vimentin binding,
hGIIA function, and arachidonic acid metabolism in synovial
inflammation. Given the importance of hGIIA in mediating
inflammation in models of arthritis (39), this mechanism also
predicts a role for vimentin in arthritis pathology and identifies
it as a potential target for drug development in this disease. In
recent years vimentin has been shown to play amuchwider role
in cell function than its traditional role as an inert cellular scaf-
fold (40). This study extends vimentin function to a lipid met-
abolic pathway important in the aberrant inflammatory
response induced in immune-mediated pathological states in
addition to an emerging functional role for vimentin in cancer
progression.
The association between vimentin and hGIIA shown here
identifies vimentin as an interesting target for further study in
other diseaseswhere a role for hGIIAhas been established. This
is particularly true in the case of tumorigenesis. Vimentin stain-
ing is frequently used as a marker for tumor identification and
progression, is a signaturemarker, along with COX-2, of tumor
dedifferentiation through the epithelial-mesenchymal transi-
tion that is a feature of cancer (41), and is increasingly being
implicated functionally in cancer pathology (42). hGIIA is over-
expressed in many cancers, and this expression has also been
functionally implicated in mediating the pathology of certain
types of cancer (43). This study suggests a potential mechanism
whereby overexpression of hGIIA may potentiate this process
that warrants further study.
When compared with small-molecule inhibitors that tradi-
tionally target catalytic sites, the manipulation of protein-pro-
tein interactions promisesmore versatility in the control of reg-
ulatory mechanisms. However, this approach is relatively
uncharted for therapeutic agents. Targeting protein-protein
interactions with small molecules is difficult as these interfaces
generally lack well defined binding pockets. Although antibody
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targeting of specific epitopes may be an effective means to
inhibit the formation of protein complexes, these are generally
expensive to produce and do not readily crossmembrane bilay-
ers. Thus, they are largely restricted to targeting extracellular
epitopes (44). Furthermore, as the interface between two pro-
teins is potentially much larger than can be covered by small
molecules, an additional challenge is to target surfaces within
these interfaces that will abrogate binding (45). In the case of
LY311727 and KH064, the location of the active site cavity,
central to the vimentin binding surface, provides a convenient
and specific tether to target the hGIIA-vimentin interaction.
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Supplemental Figure 1. Stereo image of BPB in the active site of hGIIA. 
BPB is displayed in yellow stick format, covalently bound to the active site residue His 48. 2fo-
1fc electron density contoured at 1.5	  σ	  is displayed in blue mesh and unbiased 1fo-1fc density 
contoured at 5.0 σ	  and generated before the inhibitor was included in rounds of refinement is 
displayed in green mesh. The 6 oxygen atoms coordinating the active site calcium are displayed 
with dashed lines to highlight their interaction with calcium. Apparent steric clashes are also 
highlighted with dashed lines and the distances labelled in Å	  units. HOH is also shown to be 
interacting with the carbonyl carbon (CR) on BPB. The active site calcium of the hGIIA-BPB 
complex is displayed in green. Residues directly interacting with BPB are shown in stick format 
as well as the calcium-binding loop from residues Gly30 to Arg34 and the equivalent residues 
from the structure of native hGIIA are shown as lines in magenta. The active site calcium of 
hGIIA-BPB and the native enzyme are displayed green and magenta spheres respectively.  
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Supplemental Figure 2. Comparison between current and previously published hGIIA-
KH064 (PDB accession code:1j1a) structures. 
(A) and (B) were rendered from 1j1a and the equivalent view of the current hGIIA-KH064 
structure presented in this manuscript are shown in (C) and (D). Multiple conformations of 
KH064 in 1j1a (A) contrast to two well-defined distinct conformations in the current structure 
(C). Clashes between KH064 and the calcium-binding loop in 1j1a are highlighted in (B) with 
dashed lines with distances marked. The equivalent interactions in the current structure are 
highlighted in (D).  
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Supplemental Figure 3.  hGIIA internalizes rapidly and co-localizes with vimentin.  (A-B) 
Additional examples of immunofluorescence microscopy results on RA61 FLSs treated with 
exogenous hGIIA and stained for hGIIA and vimentin as in Figure 5D. 
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Supplemental Figure 4. hGIIA internalizes rapidly and co-localizes with vimentin. 
Immunofluorescence microscopy on cells stained for hGIIA in the absence of hGIIA treatment 
(A). Exogenous hGIIA was applied and cells were stained for hGIIA in (B), vimentin (C) or 
hGIIA and vimentin in (D-E). Cells were RA57 human rheumatoid FLSs. Columns 1-3 show 
vimentin (green), hGIIA (red) and a merge image, respectively. Scale bars represent 20 µm.	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Supplemental Figure 5. Functionally selective inhibition of vimentin binding. 
Immunofluorescence microscopy on RA57 FLSs treated with (A) exogenous hGIIA alone or (B) 
hGIIA incubated with BPB. In a separate experiment, RA57 FLSs were treated with (C) 
exogenous hGIIA alone, (D) hGIIA incubated with KH064, (E) hGIIA incubated with c2, (F) 
hGIIA incubated with cF or (G) hGIIA incubated with LY311727. Staining of both hGIIA and 
vimentin was performed in all experiments. Columns 1-3 show vimentin (green), hGIIA (red) 
and a merge image, respectively. Scale bars represent 20 µm.	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